Navigation Links
Cancer risk for African-American women with benign breast disease factors Wayne State finds
Date:2/11/2013

DETROIT A Wayne State University researcher has identified characteristics in benign breast disease associated with future cancer risk in African-American women.

Michele Cote, Ph.D., associate professor of oncology in the School of Medicine and the Barbara Ann Karmanos Cancer Institute, recently reviewed data from about 1,400 20- to 84-year-old African-American women who underwent breast biopsies between 1997 and 2000. Researchers identified biopsies that showed benign breast disease (BBD) and also tracked subsequent breast cancers.

BBD is an established risk factor for breast cancer among Caucasian women, Cote said, but less is known about it in African-American women, who tend to get breast cancer earlier, in more aggressive forms and die more frequently from it.

In "Benign Breast Disease and the Risk of Subsequent Breast Cancer in African American Women," published recently in the journal Cancer Prevention Research, she said 68 percent of women studied showed nonproliferative BBD, and 29 percent had the proliferative form of the disease without atypia, a state in which cells are not growing normally but are not cancerous.

The remaining 3 percent showed proliferative BBD with atypia, a percentage similar to a group of Caucasian women studied recently by the Mayo Clinic. Women in Cote's study with the proliferative form of the disease with atypia were three times as likely to develop breast cancer as women without proliferative disease.

A number of pathological characteristics are associated with BBD and breast cancer. Her group examined several of those, including the presence of cysts, fibrosis and atrophy of breast components, known clinically as lobular involution.

Another characteristic, columnar alteration, a variation in the way cells are structured, was shown to be associated with increased breast cancer risk. Cote said because columnar alterations are highly correlated with proliferative disease, further study of the independent effects of both could be valuable.

Her team wanted to see if characteristics Mayo researchers found in white women increase or decrease risk in the same ways in black women.

"Hopefully, this eventually means the risk models that will be developed will be similar if not identical for white and black women, which simplifies usage," Cote said. "The question is, what are those pathological features that actually increase risk, because not all benign biopsies are the same."

She said her study marks a successful collaboration between Wayne State, Karmanos and the Mayo Clinic that helps identify those at greatest risk for breast cancer and lays the groundwork for studying additional pathological characteristics.

"Better characterization of the risk of breast cancer among women with BBD, considering both ethnicity and detailed molecular findings, can lead to better surveillance, earlier diagnosis and, potentially, improved survival," Cote said.

Cote received funding in 2012 from Susan G. Komen for the Cure to continue her research in the Detroit area on benign breast disease and the risk of breast cancer in African-American women.


'/>"/>

Contact: Julie O'Connor
julie.oconnor@wayne.edu
313-577-8845
Wayne State University - Office of the Vice President for Research
Source:Eurekalert  

Related biology news :

1. Tortoise and the hare: New drug stops rushing cancer cells, slow and steady healthy cells unharmed
2. Embryonic development protein active in cancer growth
3. BRG1 mutations confer resistance to hormones in lung cancer
4. Genetic variation in East Asians found to explain resistance to cancer drugs
5. Beyond the microscope: Identifying specific cancers using molecular analysis
6. Marshall University study may lead to new treatments for prostate cancer
7. Salk scientists open new window into how cancers override cellular growth controls
8. Penn research points to new way of preserving fertility for boys undergoing cancer treatment
9. Genetic abnormality offers diagnostic hope for childrens cancer
10. Protein jailbreak helps breast cancer cells live
11. Breast cancer risk gene discovery fast tracked by new technology
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer risk for African-American women with benign breast disease factors Wayne State finds
(Date:11/14/2019)... , ... November 13, 2019 , ... ... Robert Peterson, RAC , a regulatory affairs and program management executive with ... and medical device industries, has joined the firm as an Expert Consultant. ...
(Date:11/14/2019)... , ... November 13, 2019 , ... Personalized Stem ... first patients in an FDA approved clinical trial for stem cell treatment of ... formation of the company as a subsidiary of VetStem Biopharma. , In July of ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... orthopedic medical devices, today announced the creation of a Global Regulatory Affairs Department, ... Medical Device industry is that the regulatory element to any Medtech organization is ...
Breaking Biology News(10 mins):
(Date:10/30/2019)... Calif. (PRWEB) , ... October 30, 2019 , ... ... 29, 2019 to showcase the many roles innovation and technology play in educating ... Center for Innovation, featured hands-on learning opportunities and presentations by WesternU administrators and ...
(Date:10/22/2019)... ... October 22, 2019 , ... nQ Medical, Inc. of Cambridge, ... Most Fundable Companies List which was announced at a showcase event yesterday in Los ... annual revenue, strong business plans, and impressive near-term growth projections to be named one ...
(Date:10/17/2019)... ... October 16, 2019 , ... My Gene ... information, has published a new white paper that explores how frequently medical management ... to how patients and medical providers can be kept informed as changes are ...
(Date:10/10/2019)... ... October 10, 2019 , ... VirTrial today ... centers in Europe. All Pratia research centers have completed VirTrial’s Virtual Trial Capable ... certified as Virtual Trial Capable and prepared to conduct decentralized clinical trials (DCT). ...
Breaking Biology Technology: